$SNY mention timeline

Sanofi. Every tracked FinTwit mention of $SNY, newest first. 18 mentions since the first on Jun 20, 2025. See the price chart.

February 2026 · 3 mentions

Feb 12
Jacob Plieth — $SNY deserves congratulations for finding a new CEO whose track record makes Paul Hudson look good. Chapeau! https://t.co/m5qTqh6Pm5↗
Feb 12
Adam Feuerstein ✡️ — Paul Hudson out as Sanofi $SNY CEO https://t.co/HSxdB1PshV via @DrewQJoseph↗
Feb 4
Jacob Plieth — Some revelations for ADC nerds: $SNY uses the same MAb in its new CEACAM5 ADC as in the one it discontinued in 2023. Chia Tai claims a deuterated DXd payload (with no link to $DSN…↗

Jan 29
Jacob Plieth — Looks like $SNY discontinued Alphamedix/ SAR447873, licensed in Sep 2024 from Radiomedix & Orano Med, h/t B Riley. @ByMadeleineA covered it at #Esmo25 and flagged dysphagia &am…↗
Jan 23
Adam Feuerstein ✡️ — Leerink's David Risinger on the $SNY amlitelimab Karposi's sarcoma case: "As a result, we see risk of a potential black box warning on amlitelimab’s label." Would be same for $A…↗
Jan 23
Adam Feuerstein ✡️ — Perhaps I am over-reacting, but doesn't the reported case of Kaposi's sarcoma in the $SNY amlitelimab atopic dermatitis study basically end any hope for the entire OX40 drug class?…↗
Jan 15
Adam Feuerstein ✡️

Dec 8
Adam Feuerstein ✡️ — Kymera $KYMR drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial https://t.co/W3m3dtydJR via @JonathanWosen $SNY $REGN↗

Nov 19
Jacob Plieth — $GSK just followed $NVS $LLY $PFE & $SNY into myeloid cell engagers. LTZ tech seems to do this via activity at CLEC5A↗
Nov 19
Jacob Plieth — $COGT investor emphasis shifting away from mastocytosis? 95% of #Jefferies25 presentation was on 2L GIST $SNY https://t.co/NtJzAj09ke↗

Oct 10
Jacob Plieth — So basically $SNY is a pioneer https://t.co/mth5czlAgv↗
Oct 10
Jacob Plieth — Now $BMY buys Orbital for... $1.5bn! Focus seems to be autoimmune, but pipeline also includes some oncology work $AZN $ABBV $GILD $SNY $ALPMF https://t.co/rHXCOm2idI↗

Sep 19
Jacob Plieth — $BMY confirms that it scrapped its 2017 NK-cell engager tie-up with Dragonfly. With $SNY $IPHA $AFMD $GTBP setbacks this modality looks like it's on borrowed time. Via @ApexOnco -&…↗
Sep 4
Adam Feuerstein ✡️ — Sanofi $SNY shares drop after disappointing trial results. Amlitelimab falls short against Dupixent in atopic dermatitis. https://t.co/SJNDXMIIKd via @DrewQJoseph↗

Jul 22
Adam Feuerstein ✡️ — Sanofi $SNY to buy vaccine biotech Vicebio for $1.15B upfront https://t.co/Vn6nfm792T via @DrewQJoseph↗
Jul 7
Jacob Plieth — $COGT +25% as bezuclastinib safety remains in the spotlight. Via @ApexOnco -> https://t.co/c7zw3W4G5z $BPMC $SNY https://t.co/pgZlpoFn43↗

Jun 20
Jacob Plieth — @phoenicianstrat @TerryMSmith @Sanctuary_Bio TBH I thought the two scales were pretty similar. I meant more about % chg from baseline / absolute chg adjusted for placebo / >50%…↗
Jun 20
Jacob Plieth — I know that $COGT has done everything possible to muddy the endpoints, so is this basically the state of play in Summit trial vs $BPMC $SNY Ayvakit? https://t.co/XKDbXKZYDF↗